Polyendocrine metabolic ovarian syndrome (PMOS) is a hormonal condition characterised by an imbalance in reproductive hormones, particularly elevated levels of androgens (male hormones) in women. Despite the older name, not all women with the condition have cysts on their ovaries. PMOS can affect multiple body systems, influencing metabolism, fertility, and appearance. In Singapore and across Asia, PMOS affects women of reproductive age, though many cases remain undiagnosed. It often emerges during puberty but can also develop later, sometimes in response to significant weight gain.
A note on the name change: In May 2026, the condition previously known as PCOS was formally renamed polyendocrine metabolic ovarian syndrome (PMOS), following a global consensus process published in The Lancet and supported by more than 50 academic, clinical, and patient organisations worldwide, including the Endocrine Society. The new name better reflects the condition’s hormonal and metabolic complexity, moving away from a focus on ovarian cysts, which many women with the condition do not actually have. Clinical guidelines and everyday usage are expected to shift towards PMOS gradually, so you may still see the term PCOS used in some settings for the time being.